Patients affected by ASC-US/ low-grade HPV cervical lesions will be randomly assigned to treatment arm vs control arm. The treatment arm will include the characterization of the vaginal microbiota at enrollment (T0), 4 months of oral treatment with Lactobacillus Crispatus M 247 (1 buccal stick Die), characterization of the vaginal microbiota at 1 month post treatment (T5 m). The vaginal microbiota will be evaluated by Danagene microbiome vaginal DNA KIT-XMICROGem (XBIOGem) test, with amplification of the variable regions of the 16S ribosomal RNA gene, using the MICROBIOTA kit (CE-IVD - ARROW diagnostics) and second generation sequencing technologies (NGS on Illumina MiSeq platform). The control arm will provide for the characterization of the vaginal microbiota at the same timescales. Patients will be given a medical history questionnaire at T0 and T5m
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
90
Oral supplementation of Lactobacillus Crispatus M247 in patients with cervical low grade lesions HPV related
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, RM, Italy
RECRUITINGTo evaluate the efficacy of Lactobacillus Crispatus M247 oral supplementation to change the genetic profile of the vaginal microbiota of patients with low-grade lesions from HPV, by XBIOGem test.
Time frame: 5 months
Cytological regression and microbiological clearance of HPV infection
Time frame: 5 months
Evaluate the applicability in clinical practice of the XBIOGem test in the characterization of the vaginal microbiota in this type of patient
Time frame: 24 months
Evaluation of the role of anamnestic factors on the characterization of vaginal microbiota
Time frame: 24 months
Rosa Pasqualina RP De Vincenzo, Phd
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.